Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Researchers unravel the process that makes viruses infectious

Researchers have for the first time identified the way viruses like the poliovirus and the common cold virus 'package up' their genetic code, allowing them to infect cells.

8 Jan 2021

Single-dose nanoparticle vaccine for SARS-CoV-2

Before the pandemic, the lab of Stanford University biochemist Peter S. Kim focused on developing vaccines for HIV, Ebola and pandemic influenza.

8 Jan 2021

Researchers create first usable computational model of entire SARS-COV-2 virus

Researchers at the University of Chicago have created the first usable computational model of the entire virus responsible for COVID-19-;and they are making this model widely available to help advance research during the pandemic.

8 Jan 2021

Patients taking immunosuppressive drugs did not have worse COVID-19 outcomes

People taking immunosuppressive drugs to prevent organ transplant rejection or to treat inflammatory or autoimmune diseases do not fare worse than others on average when they are hospitalized with COVID-19, according to a study from researchers at the Johns Hopkins Bloomberg School of Public Health.

7 Jan 2021

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Now, an intriguing recent study appeared on the bioRxiv * preprint server describes the use of in vitro evolution to elicit affinity maturation of the viral receptor-binding domain (RBD) of the spike protein to bind the host cell angiotensin-converting enzyme 2 (ACE2) with greater affinity.

7 Jan 2021

Credible fact checking can effectively reduce vaccine misinformation on social media

Social media misinformation can negatively influence people's attitudes about vaccine safety and effectiveness, but credible organizations -- such as research universities and health institutions -- can play a pivotal role in debunking myths with simple tags that link to factual information, University of California, Davis, researchers, suggest in a new study.

7 Jan 2021

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer.

7 Jan 2021

Potential role of chitinase 3-like-1 in severity of COVID-19

Now, an intriguing preprint research paper on the bioRxiv server reports the identification of an enzyme called chitinase 3-like-1 (CHI3L1) that mediates this age-dependent impact of the virus and could serve as a powerful therapeutic approach in mitigating the severity of COVID-19 in this high-risk group.

7 Jan 2021

Innovative artistic intervention can help reduce fatal health threat to young African children

The fatal threat from diarrhea and pneumonia to young children in the world's poorer countries can be drastically reduced by using traditional performing arts to encourage mothers to provide youngsters with safe food and water, a new study reveals.

7 Jan 2021

San Francisco wrestles with drug approach as death and chaos engulf Tenderloin

In early 2019, Tom Wolf posted a thank-you on Twitter to the cop who had arrested him the previous spring, when he was homeless and strung out in a doorway with 103 tiny bindles of heroin and cocaine in a plastic baggie at his feet.

7 Jan 2021

In Los Angeles and beyond, oxygen is the latest covid bottleneck

As Los Angeles hospitals give record numbers of covid patients oxygen, the systems and equipment needed to deliver the life-sustaining gas are faltering.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Researchers who studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19 report these patients' immune memory to the virus - across all immune cell types studied - was measurable for up to 8 months after symptoms appeared.

7 Jan 2021

Adaptive immune system against COVID-19 can last for at least eight months

New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection.

6 Jan 2021

Is one-dose COVID-19 vaccination better than two?

A recent study published on the preprint server medRxiv in December 2020 reflects on the possibility of using a single-dose vaccine regimen to accomplish large-scale vaccination as early as possible.

6 Jan 2021

Low acceptance of COVID-19 vaccine among healthcare workers in USA

A recent preprint research paper published on the medRxiv server in January 2021 reports that vaccine acceptance is low even among healthcare workers (HCWs) in the USA.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Scientists develop a new method to study the molecular characteristics of T cells

UT Southwestern scientists have developed a new method to study the molecular characteristics of T cells, critical immune cells that recognize and attack invaders in the body such as viruses, bacteria, and cancer.

6 Jan 2021

Smokers at increased risk of developing symptomatic COVID-19

Smoking is associated with an increased risk of COVID-19 symptoms and smokers are more likely to attend hospital than non-smokers, a study has found.

6 Jan 2021

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Researchers unravel the process that makes viruses infectious

Single-dose nanoparticle vaccine for SARS-CoV-2

Researchers create first usable computational model of entire SARS-COV-2 virus

Patients taking immunosuppressive drugs did not have worse COVID-19 outcomes

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Credible fact checking can effectively reduce vaccine misinformation on social media

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Potential role of chitinase 3-like-1 in severity of COVID-19

Innovative artistic intervention can help reduce fatal health threat to young African children

San Francisco wrestles with drug approach as death and chaos engulf Tenderloin

In Los Angeles and beyond, oxygen is the latest covid bottleneck

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Adaptive immune system against COVID-19 can last for at least eight months

Is one-dose COVID-19 vaccination better than two?

Low acceptance of COVID-19 vaccine among healthcare workers in USA

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Scientists develop a new method to study the molecular characteristics of T cells

Smokers at increased risk of developing symptomatic COVID-19

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in